Literature DB >> 11249205

Optimal production and in vitro activity of recombinant endostatin from stably transformed Drosophila melanogaster S2 cells.

J H Park1, K H Chang, J M Lee, Y H Lee, I S Chung.   

Abstract

Recombinant plasmids containing a complementary deoxyribonucleic acid coding mouse endostatin were transfected and stably expressed in Drosophila melanogaster Schneider 2 (S2) cells. Stably transformed polyclonal cell populations expressing recombinant endostatin were isolated after 4 wk of selection with hygromycin B. Recombinant endostatin expressed in the stably transformed S2 cells under the influence of the Drosophila BiP protein signal sequence was secreted into the medium. Recombinant endostatin was also purified to homogeneity using a simple one-step Ni2+ affinity fractionation method. Purified recombinant endostatin inhibited endothelial cell proliferation in a dose-dependent manner. The concentration at maximum inhibition for recombinant endostatin was approximately 1.8 microg/ml. The stably transformed S2 cells produced 18 mg recombinant endostatin/L 7 d after induction with 5 microM CdCl2. Sodium butyrate supplementation (2.5 mM) increased recombinant endostatin production by 17%. These findings demonstrate optimal production and in vitro activity of recombinant endostatin from stably transformed D. melanogaster S2 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11249205     DOI: 10.1290/1071-2690(2001)037<0005:opaiva>2.0.co;2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  13 in total

1.  A cancer therapy resistant to resistance.

Authors:  R S Kerbel
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

2.  Purification and application of a single-chain Fv antibody fragment specific to hepatitis B virus surface antigen.

Authors:  L Canaán-Haden; M Ayala; M E Fernández-de-Cossio; I Pedroso; L Rodés; J V Gavilondo
Journal:  Biotechniques       Date:  1995-10       Impact factor: 1.993

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene.

Authors:  P Blezinger; J Wang; M Gondo; A Quezada; D Mehrens; M French; A Singhal; S Sullivan; A Rolland; R Ralston; W Min
Journal:  Nat Biotechnol       Date:  1999-04       Impact factor: 54.908

5.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

6.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

7.  Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation.

Authors:  J Arts; M Lansink; J Grimbergen; K H Toet; T Kooistra
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Substantial overproduction of antibodies by applying osmotic pressure and sodium butyrate.

Authors:  S K Oh; P Vig; F Chua; W K Teo; M G Yap
Journal:  Biotechnol Bioeng       Date:  1993-08-20       Impact factor: 4.530

Review 9.  Metal-affinity separations: a new dimension in protein processing.

Authors:  F H Arnold
Journal:  Biotechnology (N Y)       Date:  1991-02

Review 10.  Angiogenesis: an update.

Authors:  L Díaz-Flores; R Gutiérrez; H Varela
Journal:  Histol Histopathol       Date:  1994-10       Impact factor: 2.303

View more
  2 in total

1.  Successful synthesis of active human coagulation factor VII by co-expression of mammalian gamma-glutamyl carboxylase and modification of vit.K cycle in Drosophila Schneider S2 cells.

Authors:  Kotomi Nagahashi; Kazuo Umemura; Naohiro Kanayama; Takayuki Iwaki
Journal:  Cytotechnology       Date:  2017-01-09       Impact factor: 2.058

Review 2.  The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.

Authors:  Abbas Mohajeri; Sarvin Sanaei; Farhad Kiafar; Amir Fattahi; Majid Khalili; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2017-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.